2021 EAP/ECPCP联合声明:儿童和青少年SARS-CoV-2疫苗接种

2021-08-23 欧洲儿科学会 Front Pediatr

2021年8月,欧洲儿科学会(EAP)联合欧洲初级保健儿科医生联合会(ECPCP)共同发布了儿童和青少年SARS-CoV-2疫苗接种的联合声明。

中文标题:

2021 EAP/ECPCP联合声明:儿童和青少年SARS-CoV-2疫苗接种

英文标题:

SARS-CoV-2 Vaccination in Children and Adolescents-A Joint Statement of the European Academy of Paediatrics and the European Confederation for Primary Care Paediatricians

发布机构:

欧洲儿科学会

发布日期:

2021-08-23

简要介绍:

2021年8月,欧洲儿科学会(EAP)联合欧洲初级保健儿科医生联合会(ECPCP)共同发布了儿童和青少年SARS-CoV-2疫苗接种的联合声明。关于儿科人群接种SARS-CoV-2疫苗的研究数据有限,关于儿童和青少年人群接种疫苗有明显获益,但仍存在一些问题。本文通过评估当前情况,针对儿童和青少年接种SARS-CoV-2疫苗提供建议。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2021 EAP/ECPCP联合声明:儿童和青少年SARS-CoV-2疫苗接种.pdf)] GetToolGuiderByIdResponse(projectId=1, id=202091c002208363, title=2021 EAP/ECPCP联合声明:儿童和青少年SARS-CoV-2疫苗接种 , enTitle=SARS-CoV-2 Vaccination in Children and Adolescents-A Joint Statement of the European Academy of Paediatrics and the European Confederation for Primary Care Paediatricians, guiderFrom=Front Pediatr, authorId=0, author=, summary=2021年8月,欧洲儿科学会(EAP)联合欧洲初级保健儿科医生联合会(ECPCP)共同发布了儿童和青少年SARS-CoV-2疫苗接种的联合声明。, cover=https://img.medsci.cn/20211015/1634310848977_5579292.jpg, journalId=0, articlesId=null, associationId=2011, associationName=欧洲儿科学会, associationIntro=欧洲儿科学会(EAP,European Academy of Paediatrics), copyright=0, guiderPublishedTime=Mon Aug 23 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年8月,欧洲儿科学会(EAP)联合欧洲初级保健儿科医生联合会(ECPCP)共同发布了儿童和青少年SARS-CoV-2疫苗接种的联合声明。关于儿科人群接种SARS-CoV-2疫苗的研究数据有限,关于儿童和青少年人群接种疫苗有明显获益,但仍存在一些问题。本文通过评估当前情况,针对儿童和青少年接种SARS-CoV-2疫苗提供建议。</span></p>, tagList=[TagDto(tagId=116026, tagName=SARS-CoV-2疫苗接种)], categoryList=[CategoryDto(categoryId=9, categoryName=传染科, tenant=100), CategoryDto(categoryId=18, categoryName=儿科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=99655, guiderKeyword=SARS-COV-2, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6198, appHits=19, showAppHits=0, pcHits=1725, showPcHits=6177, likes=0, shares=1, comments=3, approvalStatus=1, publishedTime=Fri Oct 15 23:31:43 CST 2021, publishedTimeString=2021-08-23, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Fri Oct 15 23:17:34 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 18:41:20 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 EAP/ECPCP联合声明:儿童和青少年SARS-CoV-2疫苗接种.pdf)])
2021 EAP/ECPCP联合声明:儿童和青少年SARS-CoV-2疫苗接种.pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1062610, encodeId=db6a10626105e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=514d5556399, createdName=谷芬, createdTime=Thu Oct 21 15:24:51 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060910, encodeId=53361060910e3, content=好好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Oct 16 07:07:51 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060907, encodeId=f728106090e75, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Oct 16 07:07:27 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2021-10-21 谷芬

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1062610, encodeId=db6a10626105e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=514d5556399, createdName=谷芬, createdTime=Thu Oct 21 15:24:51 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060910, encodeId=53361060910e3, content=好好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Oct 16 07:07:51 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060907, encodeId=f728106090e75, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Oct 16 07:07:27 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2021-10-16 微探

    好好好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1062610, encodeId=db6a10626105e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=514d5556399, createdName=谷芬, createdTime=Thu Oct 21 15:24:51 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060910, encodeId=53361060910e3, content=好好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Oct 16 07:07:51 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060907, encodeId=f728106090e75, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Oct 16 07:07:27 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2021-10-16 微探

    学习学习

    0

拓展阅读

SARS-CoV-2新型冠状病毒肺炎流行期肺部手术的初步建议

中国胸心外科相关专家组(统称) · 2020-02-20

2021 多学科协作共识指南: SARS-CoV-2感染患者急性后遗症后疲劳的评估和治疗

美国物理医学与康复学会(AAPM&R,American Academy of Physical Medicine & Rehabilitation) · 2021-09-13

2021 EULAR建议:在SARS-CoV-2情况下风湿性和肌肉骨骼疾病的管理和疫苗接种(更新版)

欧洲抗风湿病联盟(EULAR,The European League Against Rheumatism) · 2022-02-23

2022 ESCMID COVID-19指南:SARS-CoV-2的诊断检测

欧洲临床微生物与感染性疾病学会(ESCMID,European Society of Clinical Microbiology and Infectious Diseases) · 2022-02-23